The regulatory role of autophagy-related miRNAs in lung cancer drug resistance.
Autophagy
Drug resistance
Lung cancer
MiRNA
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
28
01
2022
revised:
14
02
2022
accepted:
17
02
2022
pubmed:
23
2
2022
medline:
26
3
2022
entrez:
22
2
2022
Statut:
ppublish
Résumé
Autophagy is conserved cellular machinery that degrades un-usable proteins and cellular components and has a crucial role in the pathogenesis and drug resistance of various diseases such as lung cancer (LC). Multiple types of endogenous molecules (i.e. miRNAs) have been found to regulate multiple biological processes, such as autophagy. Dysfunction of these molecules is associated with the onset and progression of a variety of human malignancies. Several studies had shown that some miRNAs could mediate autophagy activity in LC cells, which would affect drug resistance as a major problem in LC therapy. Therefore, identifying the underlying molecular targets of miRNAs and their function in autophagy pathways could develop new treatment interventions for LC patients. In this review, we will summarize the interplay between miRNAs, autophagy, and drug resistance of LC patients, as well as the genes and molecular pathways that are involved.
Identifiants
pubmed: 35193040
pii: S0753-3322(22)00123-8
doi: 10.1016/j.biopha.2022.112735
pii:
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
112735Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.